Match!
Milena Music
University of Toronto
6Publications
1H-index
4Citations
Publications 6
Newest
#1Milena Music (U of T: University of Toronto)H-Index: 1
#2Antoninus Soosaipillai (MSH: Mount Sinai Hospital, Toronto)H-Index: 35
Last.Eleftherios P. DiamandisH-Index: 99
view all 6 authors...
Background Autoantibodies are produced when tolerance to self-antigens is broken and they can be mediators of tissue injury and systemic inflammation. They are excellent biomarkers because they are minimally invasive to screen and are highly abundant in serum due to limited proteolysis and slow clearance. Conventionally used methods of identifying autoantibodies in patient sera include indirect immunofluorescence, enzyme-linked immunoabsorbent assays (ELISAs) and protein microarrays. Here we pre...
1 CitationsSource
#1Milena Music (U of T: University of Toronto)H-Index: 1
#2Antoninus Soosaipillai (MSH: Mount Sinai Hospital, Toronto)H-Index: 35
Last.Eleftherios P. DiamandisH-Index: 99
view all 6 authors...
In the original version of the article [1], an error was noticed under the heading “Immunoprecipitation on protein G magnetic beads” in “Methods” section.
Source
#1Milena Music (U of T: University of Toronto)H-Index: 1
#2Marco Adelmo James Iafolla (Princess Margaret Cancer Centre)H-Index: 2
Last.Eleftherios P. Diamandis (Mount Sinai Hospital)H-Index: 99
view all 6 authors...
Immune checkpoint blockade (ICB) employs antibody-targeting of specific inhibitory receptors and ligands. The major limitations of ICB, such as high cost, limited success rate and immune-related adverse events (irAEs), highlight the need for predictive biomarkers. We analyzed pre- and post-immunotherapy serum samples of 24 patients treated with pembrolizumab for changes in PD-1 and over 1,000 additional protein markers using a multiplex proximity extension assay (PEA) to identify potential predi...
Source
#1Milena MusicH-Index: 1
view all 6 authors...
Source
#1Milena MusicH-Index: 1
view all 6 authors...
Source
#1Milena Music (U of T: University of Toronto)H-Index: 1
#2Ioannis Prassas (MSH: Mount Sinai Hospital, Toronto)H-Index: 14
Last.Eleftherios P. Diamandis (Lunenfeld-Tanenbaum Research Institute)H-Index: 99
view all 3 authors...
AbstractCancer immunotherapy, a treatment that selectively augments a patient’s anti-tumor immune response, is a breakthrough advancement in personalized medicine. A subset of cancer patients undergoing immunotherapy have displayed robust and long-lasting therapeutic responses. Currently, the spotlight is on the use of blocking antibodies against the T-cell checkpoint molecules, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programed cell death-1 (PD-1)/programed death-ligand 1 (PD-L1...
3 CitationsSource
1